United States Patent 4,978,680: Felbamate Epilepsy Method Claim, Scope, Expiration, and Patent Landscape

US Patent 4,978,680 protects a method of treating epilepsy with felbamate, chemically identified as 2-phenyl-1,3-propanediol dicarbamate. Its principal claim is broad in therapeutic scope but narrow in substance: it covers administering felbamate to reduce the incidence or severity of epileptic seizures. The patent does not claim felbamate itself, a formulation, a manufacturing process, or a particular dose.

The patent term has expired. The reported effective expiration date is December 13, 2008. The claim therefore presents no current US patent barrier to FDA-approved generic felbamate products.

What does US Patent 4,978,680 claim?

Claim 1 recites:

"A method for reducing the incidence and severity of epileptic seizures which comprises administering to a warm-blooded animal in need of such treatment a therapeutic amount of 2-phenyl-1,3-propanediol dicarbamate."

The claim has four principal elements:

Claim element	Scope
A method	Covers conduct, not a product or chemical compound
Reducing seizure incidence and severity	Requires an epilepsy-treatment result
Administration to a warm-blooded animal in need of treatment	Covers human and nonhuman warm-blooded subjects
Therapeutic amount of 2-phenyl-1,3-propanediol dicarbamate	Identifies felbamate as the active agent and requires a therapeutically effective quantity

The chemical compound identified in the claim is felbamate, marketed in the United States as Felbatol. The claim does not use the later generic name, but the chemical name is sufficient to identify the active ingredient.

What is the patent scope of the felbamate epilepsy claim?

The claim has broad coverage across treatment variables that it does not expressly limit.

Covered treatment variables

Claim 1 does not specify:

A particular dose or dosing schedule
Oral, parenteral, or another administration route
Tablet, capsule, suspension, or other dosage form
Monotherapy or adjunctive therapy
A particular seizure type
A minimum patient age
A specific disease stage or severity
A defined treatment duration
A particular pharmacokinetic profile
A specific formulation excipient

The claim could therefore cover administration of felbamate in a therapeutic amount for reducing epileptic seizures, regardless of the selected dosage form or regimen, provided the other claim requirements are met.

Limitations imposed by the claim

The claim is not unlimited. It requires:

Administration of felbamate.
A subject that is a warm-blooded animal in need of treatment.
A therapeutic amount.
Treatment directed to reducing the incidence or severity of epileptic seizures.

A use of felbamate for a non-epilepsy indication would fall outside the express claim. A formulation containing felbamate, standing alone and without the claimed method of administration, would also fall outside the claim.

The result limitation may matter in litigation. The accused treatment must be directed to seizure reduction, and the administered amount must be therapeutic. A manufacturer selling felbamate for epilepsy would have faced a substantially higher infringement risk than a manufacturer selling a chemically identical compound for an unrelated indication.

Is US Patent 4,978,680 a composition patent or a method-of-use patent?

US 4,978,680 is a method-of-use patent.

It does not claim:

Felbamate as a chemical composition
A pharmaceutical composition containing felbamate
A salt, polymorph, solvate, or crystal form
A controlled-release dosage form
A manufacturing process
A method for synthesizing felbamate
A diagnostic method
A combination of felbamate with another anticonvulsant

This distinction is commercially important. A compound patent can block manufacture and sale of the active ingredient for substantially all uses. A method patent generally requires proof that the accused party practiced, induced, or contributed to the claimed therapeutic use.

For felbamate, the patent's commercial importance came from the relationship between the claimed use and the product's FDA-approved epilepsy indications. It was not a standalone chemical monopoly.

When did US Patent 4,978,680 expire?

The effective patent term ended on December 13, 2008, based on the applicable pre-Uruguay Round filing-date term calculation generally associated with this patent. The patent was issued on December 18, 1990.

Event	Date or status
Relevant US filing date	December 13, 1988
Patent issued	December 18, 1990
Patent number	US 4,978,680
Reported effective expiration	December 13, 2008
Current enforceability	Expired

The expiration date is the key commercial fact. Any remaining claim scope has no current blocking effect in the United States because an expired patent cannot support an infringement action for post-expiration conduct.

Patent expiration does not erase historical liability. Conduct occurring before expiration could have presented infringement exposure, subject to validity, enforceability, claim construction, and other defenses. It does eliminate prospective US exclusivity based on this patent.

What was the FDA status of felbamate?

The FDA approved felbamate as Felbatol in 1993. The product received approval for serious seizure disorders, including partial seizures and Lennox-Gastaut syndrome-related seizures, subject to significant safety warnings and monitoring requirements. The approved labeling has emphasized risks including aplastic anemia and hepatic failure. [2]

The FDA label is narrower than the patent claim in some respects. The patent covers reducing epileptic seizures in a warm-blooded animal. The approved product labeling identifies specific patient populations, seizure types, and treatment uses.

This creates an important distinction:

The patent claim is drafted broadly around epilepsy treatment.
The FDA label defines the legally marketed uses for the approved product.
Generic applicants must address the patent and exclusivity information associated with the reference product under the Hatch-Waxman framework.
After patent expiration, the expired method claim no longer prevents approved generic competition.

What is the Orange Book status of felbamate and US Patent 4,978,680?

Felbatol was listed in the FDA's Orange Book as a reference product for felbamate products. The relevant patent was a use patent associated with the approved epilepsy indication. Orange Book listings support notice and certification procedures for abbreviated new drug applications, including Paragraph IV certifications while a listed patent remains relevant and unexpired. [3]

After December 2008, US Patent 4,978,680 ceased to be an enforceable Orange Book barrier. The practical consequences were:

No live patent term remained to delay generic entry.
An ANDA applicant no longer needed to defer launch because of this patent's unexpired term.
A Paragraph IV challenge to this patent would have had limited commercial value after expiration.
The patent could not support a new injunction against post-expiration generic sales.

Orange Book status should be separated from FDA approval status. An approved reference product may continue to be marketed after all listed patents expire. Patent expiration does not terminate the NDA.

Were there Paragraph IV challenges to felbamate?

A Paragraph IV certification would have been the Hatch-Waxman pathway for an ANDA applicant seeking to assert that a listed felbamate patent was invalid, unenforceable, or not infringed. The applicant's filing could have triggered patent litigation if the patent holder sued within the statutory period. [4]

For US 4,978,680, the commercial window for a Paragraph IV strategy ended with the patent's expiration in 2008. A generic applicant filing before expiration could have pursued:

Paragraph III certification, accepting launch after expiration
Paragraph IV certification, seeking approval based on an invalidity or noninfringement position
A litigation-based launch strategy
A settlement that preserved a later entry date

The available patent record does not establish a material, currently active Paragraph IV dispute involving this expired patent. No present generic-entry restriction can be based on US 4,978,680.

Which products and companies competed with Felbatol?

Felbamate competed in the anticonvulsant market with products such as valproate, carbamazepine, phenytoin, lamotrigine, topiramate, and levetiracetam. These products had different mechanisms, safety profiles, approved indications, and patent estates.

Felbatol's commercial position was constrained by its safety profile. The FDA labeling requires careful patient selection and monitoring because of potentially fatal hematologic and hepatic adverse events. [2] That safety burden reduced the relevance of a broad epilepsy method claim to routine first-line prescribing.

The competitive landscape can be summarized as follows:

Product category	Patent relevance to US 4,978,680
Branded Felbatol	Practiced the claimed felbamate epilepsy method
Generic felbamate	Entered after the patent term ended and competed directly
Other anticonvulsants	Did not practice the felbamate-specific claim
Felbamate formulations	Potentially implicated only when used for the claimed epilepsy treatment
Felbamate manufacturing suppliers	Not covered by the claim unless their conduct also supported a claimed treatment method

No biosimilar pathway applies. Felbamate is a chemically synthesized small-molecule drug, not a biologic. Competition proceeds through the ANDA framework rather than the biosimilar provisions of the Public Health Service Act.

What formulations are protected by US 4,978,680?

No formulation is expressly protected.

The claim can reach the use of a tablet, capsule, oral suspension, or other dosage form if the formulation administers a therapeutic amount of felbamate for reducing epileptic seizures. That is use coverage, not formulation coverage.

A separate formulation patent would normally require limitations such as:

Specific excipients
A defined concentration
Particle size
Release profile
Stability characteristics
Coating or dosage-form architecture
A particular ratio of ingredients

None of those limitations appears in the supplied claim. The claim therefore does not create a standalone monopoly over Felbatol tablets or suspension.

Does the patent cover felbamate manufacturing?

No. Claim 1 does not recite a process for making felbamate.

A generic manufacturer could have avoided this patent only if it also avoided practicing or inducing the claimed epilepsy treatment before expiration. The patent did not independently block:

Chemical synthesis of felbamate
Importation of felbamate API
Sale of API to a non-epilepsy customer
Development of a manufacturing process
Preparation of a dosage form as a composition

In practice, a generic product labeled for epilepsy would have created the more direct risk before expiration because the product's intended use would correspond to the patented method.

How strong was the patent estate for felbamate?

The estate associated with US 4,978,680 was strong in one dimension and limited in others.

Factor	Assessment
Therapeutic breadth	Broad within epilepsy treatment
Chemical breadth	Narrow; limited to felbamate
Formulation protection	None apparent from claim 1
Manufacturing protection	None apparent from claim 1
Dosing specificity	Broad because no dose is recited
Indication specificity	Limited to seizure reduction
Current enforceability	None; patent expired
Biosimilar relevance	None
Generic relevance	Historical Hatch-Waxman relevance only
Design-around potential before expiration	Potentially available through non-epilepsy uses, but limited for labeled epilepsy products

The claim's lack of dose, route, and formulation limitations made it difficult to design around while commercializing felbamate for epilepsy. A competitor could not avoid the claim merely by selecting a different tablet strength or dosage schedule.

The claim was still vulnerable to ordinary patent defenses, including invalidity based on anticipation or obviousness, lack of adequate written description or enablement, and noninfringement based on the absence of a therapeutic epilepsy use. Those defenses mattered before expiration. They have no prospective commercial value against current US sales because the patent is expired.

What patent litigation affects felbamate today?

US 4,978,680 does not create current patent litigation exposure. Its expiration removes the basis for a new infringement action directed to post-December 13, 2008 conduct.

Historical disputes could still matter for:

Damages claims involving pre-expiration conduct
Settlement agreements negotiated before expiration
Royalty obligations tied to past sales
Regulatory records concerning ANDA certifications
Product liability or commercial disputes unrelated to patent validity

No current US exclusivity should be assigned to this patent in a valuation of generic felbamate. Any remaining commercial risk would arise from non-patent matters, including FDA requirements, safety monitoring, supply, manufacturing quality, market demand, and labeling obligations.

What generic launch risks exist for felbamate?

The principal patent risk has ended. Generic launch risk is now regulatory and commercial rather than patent-based.

Relevant factors include:

ANDA approval requirements
Bioequivalence
Manufacturing compliance
API sourcing
Product-quality controls
Labeling and safety-monitoring obligations
Limited market size
Physician and patient acceptance
Potential supply interruptions
Competition among approved generic manufacturers

The expired patent does not prevent an approved generic from entering the US market. A new formulation or manufacturing patent, if valid and unexpired, would need to be analyzed separately from US 4,978,680.

How does US 4,978,680 compare with a compound patent?

Issue	US 4,978,680	Compound patent
Claimed subject matter	Epilepsy treatment method	Felbamate molecule or chemical class
Infringement focus	Administration for seizure reduction	Making, using, selling, or importing compound
Formulation coverage	Not express	Usually not automatic
Manufacturing coverage	None from claim 1	Often stronger if process or product-by-process claims exist
Generic challenge	Method-of-use certification issues	Direct product and use issues
Commercial leverage	Strong for labeled epilepsy use during term	Potentially broader across all uses
Current status	Expired	Requires separate patent-by-patent review

Key Takeaways

US Patent 4,978,680 is a felbamate method-of-use patent.
The claimed compound is 2-phenyl-1,3-propanediol dicarbamate, the active ingredient felbamate.
Claim 1 covers administering a therapeutic amount to a warm-blooded animal to reduce epileptic seizure incidence or severity.
The claim does not expressly cover felbamate as a composition, a formulation, or a manufacturing process.
It does not specify dose, route, seizure type, patient age, or treatment regimen.
The reported effective expiration date is December 13, 2008.
The patent presents no current US exclusivity barrier to generic felbamate.
No biosimilar pathway applies because felbamate is a small-molecule drug.
Current commercial risks are regulatory, manufacturing, safety-related, and market-based rather than patent-based.

Frequently Asked Questions

Does US Patent 4,978,680 cover all uses of felbamate?

No. It covers felbamate administration for reducing the incidence or severity of epileptic seizures. It does not expressly cover non-epilepsy uses.

Can a generic manufacturer sell felbamate after the patent expired?

Yes. Patent expiration removed the US patent barrier, subject to FDA approval, bioequivalence, manufacturing compliance, and applicable labeling requirements.

Does the patent cover Felbatol tablets and oral suspension?

Only as products used in the claimed epilepsy-treatment method. The patent does not independently claim a tablet, suspension, excipient system, or dosage-form design.

Is felbamate subject to biosimilar competition?

No. Felbamate is a chemically synthesized small molecule. Generic competition uses the ANDA pathway rather than the biosimilar pathway.

Could a new patent restore exclusivity for felbamate?

A later patent could provide separate protection for a novel formulation, manufacturing process, crystal form, combination, or treatment method if statutory patentability requirements were met. Such protection would not revive US 4,978,680.

References

United States Patent and Trademark Office. (1990). U.S. Patent No. 4,978,680: Method for reducing the incidence and severity of epileptic seizures using 2-phenyl-1,3-propanediol dicarbamate. Washington, DC: U.S. Department of Commerce.
U.S. Food and Drug Administration. (n.d.). Felbatol (felbamate) prescribing information. Silver Spring, MD: U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. Silver Spring, MD: U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2017). ANDA submissions: Content and format of an abbreviated new drug application. Silver Spring, MD: U.S. Department of Health and Human Services.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	142492	⤷ Start Trial
Germany	69028542	⤷ Start Trial
Denmark	0491094	⤷ Start Trial
European Patent Office	0491094	⤷ Start Trial
Spain	2094145	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,978,680

Summary for Patent: 4,978,680